Share page on FacebookShare page on TwitterShare page on LinkedIn
ICON plc
  • Solutions

    Solutions

    Our solutions span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.

    Read more
    Solutions
    Clinical & Scientific OperationsConsultingEarly ClinicalLaboratoriesLanguage ServicesMedical ImagingSite & Patient Solutions Strategic SolutionsSymphony Health Technologies
    End-to-end services, operational model and technology to deliver customised solutions.
    Decentralised Clinical Trial Solutions

    End-to-end services, operational model and technology to deliver customised solutions.

    Optimising real world data to drive effective outcomes and achieve regulatory authorisation.
    Real World Intelligence®

    Optimising real world data to drive effective outcomes and achieve regulatory authorisation.

  • Sectors

    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Sectors
    BiosimilarsBiotechGovernment and Public HealthMedical DevicePharmaceuticals
    Developing transformative therapies requires a flexible approach.
    Biotech

    Developing transformative therapies requires a flexible approach.

    Partners making a difference.
    ICON and You

    Partners making a difference.

  • Therapeutics

    Therapeutics

    We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.

    Read more
    Therapeutics
    CardiovascularCell and Gene TherapiesCentral Nervous SystemEndocrine & Metabolic DisordersInfectious DiseasesInternal Medicine & ImmunologyMedical DeviceOncologyPaediatricsRare & Orphan DiseasesTransplant ImmunologyWomen's Health
    ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.
    Vaccines

    ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights

    Insights

    BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.

    Read more
    Insights
    Digital Disruption Patient CentricityRegulatory IntelligenceTherapeutics insightsTransforming TrialsValue Based HealthcareBlogVideosWebinar Channel
    Establishing a platform for improvement
    Diversity and inclusion in clinical trials

    Establishing a platform for improvement

    Patient focused research for better outcomes.
    Decentralised clinical trials

    Patient focused research for better outcomes.

  • News & Events

    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    News & Events
    Press releasesIn the NewsMediakitAwardsEventsWebinarsSocial media
    18 September 2023
    Webinar: Perinatal Mood Disorders

    18 September 2023

    26 September 2023
    Webinar: Financial Times - Decentralised Clinical Trials in Focus

    26 September 2023

  • About ICON

    About ICON

    Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.

    Read more
    About ICON
    Company historyHealthcare IntelligenceICON in Asia PacificICON in Latin AmericaLeadershipQuality
    ICON CARES is our commitment to making a positive impact on our people, environment and our community.
    Environmental, Social and Governance

    ICON CARES is our commitment to making a positive impact on our people, environment and our community.

    Clinical Research. Evolved.
    Healthcare Intelligence

    Clinical Research. Evolved.

  • Careers
  • Investors
  • Investigators
  • Patients
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Press releases

Press releases

  • 27 October 2015

    ICON Reports Third Quarter 2015

    In the third quarter net revenue grew 1.8% year on year to $394.7 million.

  • 22 October 2015

    ICON Strengthens its Leadership Team in Asia Pacific with Two Key Appointments

    Mary Pan is new VP of Asia Pacific and Hiroshi Ichikawa leads ICON’s operations in Japan.

  • 21 September 2015

    ICON Receives Finalist Nomination for the 2015 Scrip Awards

    Firecrest eConsent shortlisted in best technological development in Clinical Trials category.

  • 10 September 2015

    ICON and IBM to Revolutionise Clinical Trials

    ICON applies IBM Watson clinical trial matching to oncology clinical trials.

  • 9 May 2015

    ICON Launches Medical Device & Diagnostics Research Group

    Dedicated services to support medical device manufacturers throughout the product lifecycle.

  • 2 May 2015

    ICON Completes Acquisition of MediMedia Pharma Solutions

    Extends ICON’s leadership in commercialisation and market access services and brings new scientific communications capabilities

  • 23 April 2015

    ICON Launches Electronic Informed Consent

    Part of ICONIK Informatics Hub to enhance patient engagement in the trial process, in line with FDA guidelines.

  • 23 March 2015

    ICON and Carnegie Mellon Collaborating on Informed Consent

    ICON and Carnegie Mellon University Collaborate to Evaluate Patient-centric Informed Consent Processes

  • 25 February 2015

    ICON Reports Fourth Quarter and Full Year 2014 Results and Issues 2015 Earnings Guidance

    In the fourth quarter net revenue grew 13.0% year on year to $390.

  • 2 February 2015

    ICON to Acquire MediMedia Pharma Solutions

    The acquisition strengthens ICON’s expertise in scientific communications and market access

  • 1
  • ...
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
In this section
In this section
  • Press releases
  • In the News
  • Mediakit
    • Facts and figures
    • ICON spokespeople
  • Awards
  • Events
    • Industry events
      • BioEquity Europe
    • Webinars
    • Workshops
  • Webinars
  • Social media

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media

What’s happening in ICON

ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Social media dashboard
  • LinkedIn
  • Twitter
  • Facebook
  • Instagram
  • Youtube
  • © 2023 ICON plc
  • Disclaimer
  • Privacy & Data
  • Site Cookies

Connect with us

Contact usSubmit proposal requestUpdate Email PreferencesGlobal office locatorICON on social media